CoChat

The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer

Open access
Smeltzer, Matthew P., Wynes, Murry W., Lantuejoul, Sylvie, Soo, Ross, Ramalingam, Suresh S., Varella-Garcia, Marileila, Meadows Taylor, Meghan, Richeimer, Kristin, Wood, Kelsey, Howell, Kristen E., Dalurzo, Mercedes Lilana, Felip, Enriqueta, Hollenbeck, Gina, Kerr, Keith, Kim, Edward S., Mathias, Clarissa, Pacheco, Jose, Postmus, Pieter, Powell, Charles, Tsuboi, Masahiro, Wistuba, Ignacio I., Wakelee, Heather A., Belani, Chandra P., Scagliotti, Giorgio V., Hirsch, Fred R. · 2020 · Journal of Thoracic Oncology
Cited by 192

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

INTRODUCTION Access to targeted therapies for lung cancer depends on accurate identification of patients' biomarkers through molecular testing. IASLC conducted an international survey to evaluate perceptions on current practice and barriers to implementation of molecular testing. METHODS We distributed the survey to IASLC members and other healthcare professionals around the world. The survey included a 7-question introduction for all respondents, who then answered according to one of three tracks: requesting tests/treating patients, performing/interpreting assays, or tissue acquisition. Barriers to implementing molecular testing were provided in free-response fields. The Chi-squared test was used for regional comparisons. RESULTS 2,537 respondents from 102 countries participated. Most respondents testing/treating patients believe <50% of lung cancer patients in their country receive molecular testing, but report higher rates within their own practice. Although many results varied by region, the five most frequent barriers cited in all regions were cost, quality/standards, access, awareness, and turnaround time. Many respondents expressed dissatisfaction with the current state of molecular testing for lung cancer, including 41% of those performing/interpreting assays. Issues identified included trouble understanding results (37%) and quality of the samples (23% report >10% rejection rate). Despite concerns regarding quality of testing, 47% in the performing/interpreting track stated there is no policy or strategy to improve quality in their country. Additionally, 33% of respondents who request tests/treat patients were unaware of the most recent CAP/IASLC/AMP guidelines for molecular testing. CONCLUSIONS Adoption of molecular testing for lung cancer is relatively low across the world; barriers include cost, access, quality, turn-around time, and lack of awareness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2020.05.002

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 192

Metadata

Authors
Smeltzer, M. P., Wynes, M. W., Lantuejoul, S., Soo, R., Ramalingam, S. S., Varella-Garcia, M., Meadows Taylor, M., Richeimer, K., Wood, K., Howell, K. E., Dalurzo, M. L., Felip, E., Hollenbeck, G., Kerr, K., Kim, E. S., Mathias, C., Pacheco, J., Postmus, P., Powell, C., Tsuboi, M., Wistuba, I. I., Wakelee, H. A., Belani, C. P., Scagliotti, G. V., & Hirsch, F. R.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2020-09
Volume
15
Issue
9
Pages
1434-1448
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2981991856
Cited by
192
References
10
FWCI
13.30
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.